AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
- Details
Cellceutix Corporation announced that the U.S. FDA granted rare pediatric disease designation to kevetrin for the treatment of retinoblastoma.
Read more: Retinoblastoma drug granted rare pediatric disease designation
- Details
Communicating with patients using cap color exclusively could lead to confusion and harm, especially when treating patients with more advanced disease.
- Details
A retrospective study found that a commonly prescribed drug for Parkinson’s, L-DOPA, may delay or prevent AMD.
- Details
This study adds to the growing body of literature that suggests natamycin may be more effective for treating fungal keratitis than voriconazole.
- Details
Ophthotech announced that Genentech will join Novartis and split rights to pegpleranib (Fovista) for the treatment of wet AMD.
- Details
Allergan announced that its biodegradable sustained-release bimatoprost implant is comparable to daily topical bimatoprost.
Read more: Positive results for sustained-release bimatoprost implant